Last reviewed 2026-08-25
Thymosin alpha-1 has the most substantial clinical record here and is approved in a number of countries for hepatitis B and as a vaccine adjuvant — but it is not FDA-approved in the United States, a distinction frequently blurred by vendors. The others are supported by laboratory and animal work rather than human trials.
Immune support is a goal where the evidence is unusually geographically split. Thymosin alpha-1 has been used clinically for decades in Europe and Asia and carries real trial data, while never having secured FDA approval in the US.
That distinction is worth holding onto, because 'approved' without a country attached is one of the most common ways peptide marketing overstates its case.
The antimicrobial peptides are a different situation again: LL-37 is a genuine part of human innate immunity and is under active research, but administering it as a therapy is not established practice.
Every entry carries the level of human evidence for this use — not the compound’s approval status for something else.
| Peptide | Evidence for this goal | FDA status | Typical cost/mo |
|---|---|---|---|
| Thymosin Alpha-1 | Human trials, not approved for this use | Research | $200–$500 |
| LL-37 | Animal studies only | Research | $150–$400 |
| KPV | Animal studies only | Research | $80–$250 |
Immunomodulator that supports T-cell function; used clinically for hepatitis B and as a vaccine adjuvant.
The catch: Approved in numerous countries but not by the FDA in the United States. Anyone told it is 'FDA-approved' is being misinformed.
Human cathelicidin antimicrobial peptide, part of innate immune defence.
The catch: A real and important component of human immunity, but giving it as a therapy is supported by laboratory work rather than clinical trials.
Anti-inflammatory tripeptide derived from alpha-MSH.
The catch: Animal and cell studies only.
Thymosin alpha-1, which has decades of clinical use and trial data outside the United States, though not FDA approval within it.
Medical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.
Thymosin Alpha-1 requires a prescription and medical supervision. Each service below states that a licensed provider reviews your intake and prescribes through a US compounding pharmacy where appropriate. Those are the companies’ own descriptions of how they operate, not findings of ours. Compounded medications are not FDA-approved, and a consultation does not guarantee a prescription.
Some telehealth links below are affiliate links. If you buy through them, we may earn a commission at no extra cost to you. Commission never affects which products or clinics we list, how they are ordered, or what we say about them — see our editorial policy.
Says a board-certified physician reviews each intake and prescribes through a licensed 503A compounding pharmacy where appropriate, and lists a LegitScript certification. Compounded medications are not FDA-approved.
We are not a clinic and do not prescribe. Listing a service here is not a clinical endorsement of it, and you should confirm licensure and pharmacy sourcing yourself before treatment.
No. It is approved in a number of other countries for hepatitis B and as a vaccine adjuvant, and it has a substantial clinical record there, but it has not been approved by the FDA in the United States. In the US it is supplied through compounding.
Immunomodulators can in principle affect autoimmune disease in either direction, which is precisely why this is not a self-directed decision. None of these compounds is approved in the US for an autoimmune indication, and anyone with an autoimmune condition should be working with a physician managing it.
Our directory lists clinics whose own websites show they offer peptide therapy. We verify what each one actually provides rather than taking a listing at face value.
Browse the provider directory